Valuation: Insmed Incorporated

Market Cap 27.02B 23.33B 21.89B 19.93B 37.48B 2,584B 38B 257B 101B 1,294B 101B 99.26B 4,306B P/E 2026 *
-78.2x
P/E 2027 * 122x
Enterprise Value 26.39B 22.78B 21.37B 19.47B 36.61B 2,523B 37.11B 251B 98.19B 1,264B 99.08B 96.94B 4,205B EV / Sales 2026 *
14.6x
EV / Sales 2027 * 9.02x
Free-Float
99.49%
Yield 2026 *
-
Yield 2027 * -
1 day+2.84%
1 week-5.81%
Current month+28.73%
1 month+17.18%
3 months+18.46%
6 months-15.68%
Current year-27.07%
1 week 122.21
Extreme 122.21
135.3
1 month 96.42
Extreme 96.42
137.7
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 21.21
Extreme 21.21
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Director of Finance/CFO 45 2020-01-30
Chief Tech/Sci/R&D Officer 62 2019-12-18
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 72 2014-05-28
Date Insider Type Main position Quantity % Market Cap.
8/10/26 Fiscal year

Chief Operating Officer

719,550 0.3320%
8/6/26 Fiscal year

Chief Technology Officer

81,519 0.0376%
7/23/26 Fiscal year

Chief Executive Officer

32,100 0.0148%
Change 5-day change 1-year change 3-year change Capi.($)
+3.11%-5.81%-0.27%+477.72% 27.02B
+4.80%+7.80%+70.64%+114.21% 70.07B
+17.12%+11.50%+49.15%+87.30% 52.87B
+2.26%+0.65%+49.19%+10.30% 23.61B
-1.50%-1.28%-18.60%-19.08% 23.38B
-6.00%+13.71%+244.39%+443.26% 19.43B
+3.80%+5.62%+39.57%-15.26% 18.75B
+0.38%-3.15%+20.39%+589.77% 15.85B
+1.97%-1.10%+38.72%+149.43% 12.7B
+2.22%+0.20%+344.55%+205.00% 12.24B
Average +2.80%-2.00%+83.77%+204.26% 27.59B
Weighted average by Cap. +4.90%-1.15%+68.10%+171.81%

Financials

2026 *2027 *
Net sales 1.81B 1.56B 1.46B 1.33B 2.51B 173B 2.54B 17.15B 6.72B 86.53B 6.78B 6.64B 288B 2.87B 2.48B 2.32B 2.12B 3.98B 274B 4.03B 27.22B 10.67B 137B 10.77B 10.53B 457B
Net income -341M -294M -276M -251M -473M -32.58B -479M -3.24B -1.27B -16.32B -1.28B -1.25B -54.3B 204M 176M 165M 150M 283M 19.49B 287M 1.93B 758M 9.76B 765M 749M 32.47B
Net Debt -632M -545M -512M -466M -876M -60.41B -889M -6B -2.35B -30.27B -2.37B -2.32B -101B -1.16B -999M -937M -853M -1.6B -111B -1.63B -10.98B -4.3B -55.4B -4.34B -4.25B -184B
Logo Insmed Incorporated
Insmed Incorporated specializes in the research and development of drugs for the treatment of respiratory, immunological, inflammatory, neurological, and rare diseases. At the end of 2025, the group has two products in the commercialization phase: ARIKAYCE® for the treatment of lung infection caused by the Mycobacterium avium complex and BRINSUPRI® for the treatment of bronchiectasis (dilation of the bronchi) unrelated to cystic fibrosis. The United States account for 74.7% of net sales.
Employees
1,664
Date Price Change Volume
26-08-17 US$126.86 +2.52% 716,696
26-08-14 US$123.74 -2.05% 1,957,324
26-08-13 US$126.33 -4.50% 2,479,563
26-08-12 US$132.28 -0.22% 1,563,224
26-08-11 US$132.57 -1.62% 2,728,711
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
123.74USD
Average target price
200.05USD
Spread / Average Target
+61.67%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock